Abstract: The purpose of the present invention is to provide a novel urethane decomposing method by which urethane in the environment is treated efficiently and at a low cost, and a urethane decomposing agent. The above purpose is attained by employing a urethane decomposing method including: a step of treating a urethane-containing material to be treated using an unsaturated fatty acid; and a step of making a microorganism belonging to a Streptomyces genus and exhibiting urethane decomposing function, to act on the material treated using the unsaturated fatty acid.

Abstract: A technology for producing a pig edema disease vaccine at low cost and at high efficiency is developed. Specifically, a gene of a pig edema disease toxin protein (Stx2e protein) is efficiently expressed in plant cells to produce a plant vaccine for pig edema disease at low cost. An Stx2e protein including a secretory signal peptide derived from a plant added at an amino terminus is expressed in cells of a plant such as Lactuca sativa using the 5?-untranslated region of an alcohol dehydrogenase gene (ADH5?UTR) derived from a plant.

Abstract: A vaccine preparation characterized in that Neospora caninum-derived dense granule protein 7 or apical membrane antigen 1 or an immunologically active variant or derivative thereof is included in liposomes each having an oligosaccharide capable of binding to a carbohydrate recognition molecule on the surface of antigen-presenting cells on the surface of the liposome.

Abstract: A method for producing an ?-Gal-expressing virus having enhanced immune response to viruses, without requiring the use of any enzyme; an influenza virus vaccine having a high effect (antigenicity), which is produced using an ?-Gal-expressing virus produced by the method; and others. Specifically disclosed are: a method for producing an ?-galactose epitope (Gal?1-3Gal?1-4GlcNAc-R: ?-Gal hereinafter)-expressing virus, which comprises the steps of: (1) introducing an ?1,3- galactosyltransferase gene in an expressible condition into a cell line that does not express ?-Gal to obtain a cell line capable of expressing ?-Gal; (2) inoculating a virus into the cell line capable of expressing ?-Gal to obtain a cell line infected with a virus; and (3) culturing the cell line infected with the virus to obtain a virus expressing ?-Gal from the culture medium..

Abstract: The object is to develop an antiprotozoal remedy having a novel mechanism of action. Provided is a compound represented by a chemical formula (1), a prodrug or a pharmaceutically acceptable salt thereof, wherein within the formula (1), R1 represents R10— of formula (4) or R20— of formula (5); R2 represents CHO—, etc.; R3 represents a hydrogen atom, CH3—C(?O)—, etc.; R4 represents a hydrogen atom, CH3—C(?O)—, etc.; each of R11 and R12 independently represents each a hydrogen atom, a methyl group, etc.; R13 represents —CH2—, —CH(—OH)— or —C(?O)—; each of R21 and R22 independently represents eaeh a hydrogen atom, a methyl group, etc.; R23 represents —CH2—, —CH(—OH)— or —C(?0)—; and R24 represents a hydrogen atom, a hydroxyl group, a methyl group, etc.

Abstract: Compositions for protecting transplanted organs, promoting survival of transplanted organs or preserving organs for transplant containing erythropoietin (EPO) as an active ingredient are provided.

Abstract: A monoclonal antibody which recognizes abnormal type prion protein alone is disclosed. By the present invention, an anti-abnormal type prion monoclonal antibody whose corresponding antigen is an abnormal type prion protein, and which does not substantially react with normal type prion protein was first provided. Since the corresponding antigen of the monoclonal antibody according to the present invention is the naturally occurring abnormal type prion protein, measurement of the abnormal type prion protein may be attained with high sensitivity.